Article Information
History
- April 21, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ming Zhong*,1,2,
- Aijun Sun*,3,4,
- Ting Xiao5,
- Ge Yao5,
- Ling Sang6,
- Xia Zheng7,
- Jinyan Zhang3,
- Xuejuan Jin3,
- Lei Xu3,
- Wenlong Yang3,
- Peng Wang3,
- Kai Hu3,
- Dingyu Zhang#,2 and
- Junbo Ge#,3,4
- 1Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
- 2Wuhan JinYinTan Hospital, Wuhan, China
- 3Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China
- 4Institute of Biomedical Sciences, Fudan University, Shanghai, China
- 5Intensive Care Unit of the Six Floor of South Building, Wuhan JinYinTan Hospital, Wuhan, China
- 6The First Affiliated Hospital of GuangZhou Medical University, GuangZhou Institute of Respiratory Health, Department of Critical Care Medicine. Guangzhou,China
- 7Department of Critical Care Medicine, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
- ↵#Corresponding author Junbo Ge, M.D., Department of cardiology, Zhongshan Hospital, Fudan University; Shanghai Cardiovascular Medical Center; Shanghai Institute of Cardiovascular Diseases, Institute of Pan-vascular Medicine., 1609Xietu Road, Shanghai 200032, PR China., Tel.: + 86-21-64041990 ext 2745; Fax: +86-21-64223006; E-mail: jbge{at}zs-hospital.sh.cn, Dingyu Zhang, M.D., Wuhan JinYinTan Hospital, Wuhan, China, No.1 Yintan Road, Dongxihu District, Wuhan; E-mail:1813886398{at}qq.com
↵* Contributed equally to this work
Posted April 21, 2020.
A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019(COVID-19)
